Introduction: There are 25 million individuals in the United States with limited English proficiency (LEP). Language barriers contribute to poorer patient assessment, misdiagnosed and/or delayed treatment, and inadequate understanding of the patient condition or prescribed treatment. LEP also has been shown to result in inadequate pain control, yet there are significant gaps in our knowledge related to pain documentation and pain management in primary care settings. The objective of this study is to describe and compare pain documentation for LEP racial/ethnic minority patients - Hmong-speaking Asian and Spanish-speaking Latinx - to English-speaking White patients with moderate to severe pain at an academic primary care clinic.

Methods: We conducted a retrospective mixed methods electronic health record study of patients age ≥ 18 with a pain score of ≥ 6; preferred language of Hmong, Spanish, or English; and evaluation in a primary care clinic. Abstracted data included characteristics of the provider, patient, interpreter, and pain care process. Descriptive statistics, analysis of variance, and chi-square tests were used. Clinician subjective assessment was analyzed using directed content analysis.

Results: Three hundred forty-two patient visits were included. Pain score distribution differed by patient language and race/ethnic group ( < 0.001), with an average pain score of 7.66 (SD 1.25). Interpreter type varied between the LEP groups ( = 0.009). Pain location was documented in a higher percentage of visits overall (87%) and more frequently for English-speaking White and Spanish-speaking Latinx patient visits than Hmong-speaking Asian visits ( < 0.001). Pain quality, onset, and duration were documented more frequently in LEP patient visits than English-speaking White patient visits (all  < 0.001). While overall opioid prescription rates were low, opioids were prescribed 3 times more frequently to English-speaking White patients than LEP patients ( = 0.002). Approximately 20% of patients were prescribed nonpharmacological treatment.

Conclusion: Pain care process and treatment documentation varied by patient language and race/ethnicity. Future studies could evaluate the impact of pain assessment and treatment documentation on pain outcomes for LEP patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

primary care
16
pain
9
documentation pain
8
pain care
8
limited english
8
english proficiency
8
minority patients
8
pain documentation
8
pain score
8
care
6

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Axsome Therapeutics, New York, NY, USA.

Background: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.

View Article and Find Full Text PDF

In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.

View Article and Find Full Text PDF

Intubation of patients requiring cervical spine immobilization can be challenging. Recently, the use of C-MAC video laryngoscopes (VL) has increased in popularity over direct laryngoscopy (DL). We aimed to conduct a systematic review and meta-analysis to evaluate the efficacy of C-MAC VL as compared with DL for intubation in C-spine immobilized patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!